Fumiya Hirano
- Immunology top 0.5%
- Immunotherapy and Immune Responses 5
- Aquaculture disease management and microbiota 2
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 4
- CAR-T cell therapy research 3
- Cancer Research top 5%
- Carcinogens and Genotoxicity Assessment 3
- Genetics top 5%
-
- Antibiotic Resistance in Bacteria 3
-
- Microbial infections and disease research 3
-
- Liver physiology and pathology 2
- Co-authors
- Lieping ChenDallas B. FliesKoji TamadaHaidong DongHideto TamuraGefeng ZhuScott E. StromeDiva R. Salomão
- Cited by
- ImmunologyOncologyCancer Research
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Fumiya Hirano
21 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Immunology 3.4k
- Oncology 4.2k
- Cancer Research 359
- Pulmonary and Respiratory Medicine 688
- Genetics 174
Countries citing papers authored by Fumiya Hirano
This map shows the geographic impact of Fumiya Hirano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumiya Hirano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumiya Hirano more than expected).
Fields of papers citing papers by Fumiya Hirano
This network shows the impact of papers produced by Fumiya Hirano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumiya Hirano. The network helps show where Fumiya Hirano may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fumiya Hirano, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 2 | |
| 2 | 2016 | 8 | |
| 3 | 2014 | 18 | |
| 4 | 2014 | 17 | |
| 5 | 2013 | 1 | |
| 6 | 2013 | 3 | |
| 7 | Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunitybreakdown → | 2005 | 794 |
| 8 | 2004 | 152 | |
| 9 | B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. | 2003 | 400 |
| 10 | Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionbreakdown → | 2002 | 3972 |
| 11 | 2002 | 3 | |
| 12 | The effects of various antibacterial agents on the release of verotoxin against Escherichia coli O-157: H7 strains | 1997 | 5 |
| 13 | Modification of T-lymphocyte subsets in peripheral blood, the liver, and the spleen during liver regeneration after partial hepatectomy of mice. | 1994 | 2 |
| 14 | 1992 | 1 | |
| 15 | 1991 | 31 | |
| 16 | 1990 | 4 | |
| 17 | 1984 | 9 | |
| 18 | [The mutagenicity evaluation of MT-141, a new cephamycin]. | 1984 | 3 |
| 19 | 1983 | 14 | |
| 20 | 1981 | 7 |
About Fumiya Hirano
Fumiya Hirano is a scholar working on Microbiology, Molecular Medicine and Immunology, having authored 21 papers that have together received 5.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Carcinogens and Genotoxicity Assessment (3 papers), CAR-T cell therapy research (3 papers), Antibiotic Resistance in Bacteria (3 papers), Microbial infections and disease research (3 papers), Aquaculture disease management and microbiota (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Immunology (3.4k citations), Oncology (4.2k citations) and Cancer Research (359 citations). Fumiya Hirano has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Lieping Chen, Dallas B. Flies, Koji Tamada, Haidong Dong, Hideto Tamura, Gefeng Zhu, Scott E. Strome, Diva R. Salomão, Jun Lü and Patrick C. Roche. Their work appears in journals such as Nature Medicine, The Journal of Immunology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.